HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted ...

Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Explore Syndax Pharmaceuticals' Q4 2024 earnings highlights, including strong Revuforj launch revenue, label expansion plans, and a $2 billion ...

Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...